Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review suggests that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have potential benefits for dermatologic conditions but may also cause adverse skin reactions and impact surgical outcomes.

This review examines how GLP-1 receptor agonists might impact metabolic and reproductive outcomes in polycystic ovary syndrome, but it reports no new clinical findings and highlights the need for further research.

This review suggests weak associations between GLP-1 receptor agonists and increased reports of hair loss, particularly with semaglutide and tirzepatide, while cases of hair regrowth were also occasionally documented.

This review highlights concerns about dermatological side effects linked to rapid weight loss from glucagon-like peptide-1 receptor agonists used for type 2 diabetes and obesity treatment, such as skin laxity, decreased collagen, and hair loss, emphasizing the importance of managing these while retaining metabolic benefits.

This review discusses the roles and therapeutic effects of GLP-1 receptor agonists on the nervous, cardiovascular, and endocrine systems, but reports no new clinical results, emphasizing the need for further research on their impact on metabolism and tumor relationships in type 2 diabetes patients.